Abstract
Alzheimers Disease (AD) is a progressive neurodegenerative disorder marked by loss of memory, cognition, and behavioral stability. AD is defined pathologically by extracellular neuritic plaques comprised of fibrillar deposits of β-amyloid peptide (Aβ) and neurofibrillary tangles comprised of paired helical filaments of hyperphosphorylated tau. Current therapies for AD, such as cholinesterase inhibitors, treat the symptoms but do not modify the progression of the disease. The etiology of AD is unclear. However, data from familial AD mutations (FAD) strongly support the “amyloid cascade hypothesis” of AD, i.e. that neurodegeneration in AD is initiated by the formation of neurotoxic β-amyloid (Aβ) aggregates, all FAD mutations increase levels of Aβ peptide or density of Aβ deposits. The likely link between Aβ aggregation and AD pathology emphasizes the need for a better understanding of the mechanisms of Aβ production. This review summarizes current therapeutic strategies directed at lowering Aβ levels and decreasing levels of toxic Aβ aggregates through (1) inhibition of the processing of amyloid precursor protein (APP) to Aβ peptide, (2) inhibition, reversal or clearance of Aβ aggregation, (3) cholesterol reduction and (4) Aβ immunization.
Keywords: alzheimer disease, amyloid precursor protein, beta-amyloid, beta-secretase, gamma-secretase, aggregation, cholesterol, vaccine
Current Pharmaceutical Design
Title: Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Volume: 9 Issue: 6
Author(s): Kelly A. Conway, Ellen W. Baxter, Kevin M. Felsenstein and Allen B. Reitz
Affiliation:
Keywords: alzheimer disease, amyloid precursor protein, beta-amyloid, beta-secretase, gamma-secretase, aggregation, cholesterol, vaccine
Abstract: Alzheimers Disease (AD) is a progressive neurodegenerative disorder marked by loss of memory, cognition, and behavioral stability. AD is defined pathologically by extracellular neuritic plaques comprised of fibrillar deposits of β-amyloid peptide (Aβ) and neurofibrillary tangles comprised of paired helical filaments of hyperphosphorylated tau. Current therapies for AD, such as cholinesterase inhibitors, treat the symptoms but do not modify the progression of the disease. The etiology of AD is unclear. However, data from familial AD mutations (FAD) strongly support the “amyloid cascade hypothesis” of AD, i.e. that neurodegeneration in AD is initiated by the formation of neurotoxic β-amyloid (Aβ) aggregates, all FAD mutations increase levels of Aβ peptide or density of Aβ deposits. The likely link between Aβ aggregation and AD pathology emphasizes the need for a better understanding of the mechanisms of Aβ production. This review summarizes current therapeutic strategies directed at lowering Aβ levels and decreasing levels of toxic Aβ aggregates through (1) inhibition of the processing of amyloid precursor protein (APP) to Aβ peptide, (2) inhibition, reversal or clearance of Aβ aggregation, (3) cholesterol reduction and (4) Aβ immunization.
Export Options
About this article
Cite this article as:
Conway A. Kelly, Baxter W. Ellen, Felsenstein M. Kevin and Reitz B. Allen, Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease, Current Pharmaceutical Design 2003; 9 (6) . https://dx.doi.org/10.2174/1381612033391649
DOI https://dx.doi.org/10.2174/1381612033391649 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Current Pharmaceutical Design <i>In Silico</i> Identification of Irreversible Cathepsin B Inhibitors as Anti- Cancer Agents: Virtual Screening, Covalent Docking Analysis and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Antioxidant Agents in Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Prediction of miRNA in Human MHC that Encodes Different Immunological Functions Using Support Vector Machines
Current Bioinformatics Analysis of NCL Proteins from an Evolutionary Standpoint
Current Genomics Differential Effects of Nicotine Exposure on the Hippocampus Across Lifespan
Current Neuropharmacology TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy
Current Medical Imaging Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Advances in the Discovery of Novel Positive Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor
Recent Patents on CNS Drug Discovery (Discontinued)